Moderna Stock

Moderna P/FCF

The P/FCF (Price-to-Free-Cash-Flow Ratio) of Moderna (MRNA) as of Aug 2, 2026 is -7.99. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was -4.07 — a change of 96.37% (lower).

P/FCF

-7.99

YoY

96.37%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of Moderna is 2026 -7.99 . P/FCF (Price-to-Free-Cash-Flow Ratio) of Moderna was 2025 -4.07 . It decreases by 96.37% lower compared to the previous year.
Access this data via the Eulerpool API

Moderna Stock analysis

What does Moderna do? Moderna Inc is a biotechnology company from the USA that specializes in the development of therapies and vaccines based on mRNA technology. The company was founded in 2010 by a group of researchers led by Noubar Afeyan and is headquartered in Cambridge, Massachusetts. Moderna is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Moderna stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of Moderna is -7.99 in 2026.

Access this data via the Eulerpool API

Valuation — Moderna

All Key Metrics — Moderna